A first-in-class GPR183 antagonist was developed for the treatment of rheumatoid arthritis.
A first-in-class GPR183 antagonist was developed for the treatment of rheumatoid arthritis.
Cpyright © 2023 Nanjing Immunophage Biotech Co.,Ltd All Rights Reserved.
Click here to learn more